QQ客服 官方微博 反馈留言

	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study
	Sun, Yinghao; Zou, Qing; Sun, Zhongquan; Li, Changling; Du, Chuanjun; Chen, Zhiwen; Shan, Yuxi; Huang, Yiran; Jin, Jie; Ye, Zhang Qun
	2016
卷号	23期号:5页码:404-411
关键词	abiraterone acetate Asian population castration-resistant prostate cancer docetaxel phase 3
ISSN号	0919-8172
DOI	10.1111/iju.13051
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383201
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Sun, Yinghao,Zou, Qing,Sun, Zhongquan,et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study[J],2016,23(5):404-411.
APA	Sun, Yinghao.,Zou, Qing.,Sun, Zhongquan.,Li, Changling.,Du, Chuanjun.,...&Ye, Dingwei.(2016).Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.,23(5),404-411.
MLA	Sun, Yinghao,et al."Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study".23.5(2016):404-411.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。